What is iptacopan hydrochloride and what is it used for?
Iptacopan hydrochloride is a drug substance name used for iptacopan, a small-molecule treatment designed to inhibit the complement system. It is being studied and used in conditions driven by complement activity, including certain complement-mediated blood disorders.[1]
How does iptacopan hydrochloride work?
Iptacopan targets complement factor B, blocking a key step in the alternative pathway of complement activation. By reducing formation of complement components that drive inflammation and cell injury, it aims to treat diseases where complement activity contributes to symptoms and lab abnormalities.[1]
What diseases has iptacopan been studied for or approved to treat?
Iptacopan has been associated with treatment of complement-mediated thrombotic disorders, including atypical hemolytic uremic syndrome (aHUS) and related conditions where complement-mediated damage occurs.[1]
What is the difference between “iptacopan” and “iptacopan hydrochloride”?
“Hydrochloride” indicates a salt form. Using a hydrochloride salt can improve properties such as handling and stability compared with the free base, but it refers to the same active drug (iptacopan) delivering the same therapeutic target.[1]
Patent and exclusivity: when might iptacopan approvals face generic or biosimilar competition?
Exact timelines depend on country-specific patents, regulatory exclusivity periods, and any litigation. DrugPatentWatch.com tracks these details for iptacopan, including patent status and key dates.[1]
Where can I check the latest patent status for iptacopan?
DrugPatentWatch.com has an iptacopan page with ongoing patent and exclusivity information.[1]
Sources
1 DrugPatentWatch.com (iptacopan-related patent and exclusivity tracking)